

## POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby ar	ppoint:					
Practiti	oners associated with the Customer Number	20350				
OR	L.					
Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):						
	Name		Registra	ation Number		
			·			
as attomey(	s) or agent(s) to represent the undersigned before th	e United States I	Patent and Trad	emark Office (USPTO) in connection with		
any and all p	patent applications assigned only to the undersigned this form in accordance with 37 CFR 3.73(b).	according to the	USPIO assigni	ment records or assignment documents		
Assignee Na	ame and Address:			·		
	Elan Pharmaceuticals, Inc.			RECEIVED		
	800 Gateway Blvd.					
South San Francisco, CA 94080				SEP 2 8 2004		
	. *			OFFICE OF PETITIONS		
A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.						
SIGNATURE of Assignee of Record  The individual whose signature and title is supplied below is authorized to act on behalf of the assignee						
Name	Carl Battle					
Signature	Conf h. B		Date	Aus. 11, 2004		
Title	Senior Vice-President, Chief Patent Counsel		Telephone			

60265801 v1

PTO/SB/96 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Attorney Docket No. 015270-006430US

<u>STA</u>	TEMENT UNDER 37 CFR 3.73(b)					
Applicant/Patent Owner: John P. Anderson	n et al.					
Application No./Patent No.: 09/471,669 Filed/Issue Date: December 24, 1999						
Entitled: Beta-Secretase Enzyme Compos	sitions and Methods					
Elan Pharmaceuticals, Inc.	, a Corporation					
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)						
states that it is:						
1. 🔀 the assignee of the entire right, title, and interest; or						
2. an assignee of less than the entire right, title and interest.  The extent (by, percentage) of its ownership interest is%						
in the patent application/patent identified at	bove by virtue of either:					
	of the patent application/patent identified above. The assignment atent and Trademark Office at Reel <u>012618</u> , Frame <u>0961</u> , or for					
OR						
B. A chain of title from the inventor(s), c as shown below:	of the patent application/patent identified above, to the current assignee					
1. From:	То:					
	the United States Patent and Trademark Office at or which a copy thereof is attached.					
2. From:	То :					
The document was recorded in	the United States Patent and Trademark Office at RECEN	VED				
Reel, Frame, or fo	as which a convert area of its attached					
Additional documents in the cha	ain of title are listed on a supplemental sheet.	<u> 2004</u>				
☐ Copies of assignments or other documents in the chain of title are attached.						
	al assignment document or a true copy of the original document) on in accordance with 37 CFR Part 3, if the assignment is to be See MPEP 302.8]					
The undersigned (whose title is supplied be	elow) is authorized to act on behalf of the assignee.					
October 2, 200	عد ه Jean M. Duvall					
Date	Typed or printed name					
	M Signature					
	Vice President, Intellectual Property					
•	Title					

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231\_DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.